- Home
- ELVN vs PLSE Comparison
ELVN vs PLSE Comparison
Compare ELVN & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | PLSE |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ELVN | PLSE |
|---|---|---|
| Price | $25.42 | $13.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $41.00 | $22.00 |
| AVG Volume (30 Days) | ★ 1.5M | 197.6K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $86,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,002.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.30 | $12.56 |
| 52 Week High | $29.98 | $25.00 |
Technical Indicators
Market Signals| Indicator | ELVN | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 71.40 | 45.28 |
| Support Level | $23.25 | $13.17 |
| Resistance Level | $29.98 | $15.65 |
| Average True Range (ATR) | 1.98 | 0.86 |
| MACD | 1.30 | 0.02 |
| Stochastic Oscillator | 70.12 | 29.90 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.